Evidence map›Paper›PMID 37949070›Full record

ArticleCell reports. Medicine2023

Dominant CD4

Alexis Sponaugle, Ann Marie K Weideman, Jolene Ranek, Gatphan Atassi, JoAnn Kuruc, Adaora A Adimora, Nancie M Archin, Cynthia Gay, Daniel R Kuritzkes, David M Margolis and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Alexis SponaugleDepartment of Microbiology & Immunology, UNC Chapel Hill, Chapel Hill, NC, USA.
Ann Marie K WeidemanDepartment of Biostatistics, UNC Chapel Hill, Chapel Hill, NC, USA; Center for AIDS Research, School of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA.
Jolene RanekComputational Medicine Program, UNC Chapel Hill, Chapel Hill, NC, USA; Curriculum in Bioinformatics and Computational Biology, UNC Chapel Hill, Chapel Hill, NC, USA.
Gatphan AtassiLineberger Comprehensive Cancer Center, UNC Chapel Hill, Chapel Hill, NC, USA.
JoAnn KurucDepartment of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA.
Adaora A AdimoraCenter for AIDS Research, School of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA; Department of Epidemiology, Gillings School of Global Public Health, UNC Chapel Hill, Chapel Hill, NC, USA.
Nancie M ArchinDepartment of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA.
Cynthia GayDepartment of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA.
Daniel R KuritzkesDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
David M MargolisDepartment of Microbiology & Immunology, UNC Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA.
Benjamin G VincentDepartment of Microbiology & Immunology, UNC Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA; Curriculum in Bioinformatics and Computational Biology, UNC Chapel Hill, Chapel Hill, NC, USA.
Natalie StanleyComputational Medicine Program, UNC Chapel Hill, Chapel Hill, NC, USA; Department of Computer Science, UNC Chapel Hill, Chapel Hill, NC, USA.
Michael G HudgensDepartment of Biostatistics, UNC Chapel Hill, Chapel Hill, NC, USA; Center for AIDS Research, School of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA.
Joseph J EronDepartment of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA.
Nilu GoonetillekeDepartment of Microbiology & Immunology, UNC Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, UNC Chapel Hill, Chapel Hill, NC, USA. Electronic address: nilu_goonetilleke@med.unc.edu.
University of North Carolina at Chapel Hill · USBrigham and Women's Hospital · US

Funding

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6M
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1U01AI131310 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GOONETILLEKE, NILU · 2017 to 2023
$7.2M
Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation.R37CA247676 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VINCENT, BENJAMIN G · 2020 to 2025
$3.6M
NCI NIH HHS P30 CA016086NCI NIH HHS R37 CA247676NIAID NIH HHS P30 AI050410NIAID NIH HHS U01 AI131310NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI164567
6 · The paper itself

Abstract

In people with HIV (PWH), the post-antiretroviral therapy (ART) window is critical for immune restoration and HIV reservoir stabilization. We employ deep immune profiling and T cell receptor (TCR) sequencing and examine proliferation to assess how ART impacts T cell homeostasis. In PWH on long-term ART, lymphocyte frequencies and phenotypes are mostly stable. By contrast, broad phenotypic changes in natural killer (NK) cells, γδ T cells, B cells, and CD4

Indexed as

HIV InfectionsImmune ReconstitutionAnti-Retroviral AgentsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHumansReceptors, Antigen, T-CellAnti-Retroviral AgentsReceptors, Antigen, T-Cellantiretroviral therapyHIVhomeostasishumanlatencymass cytometryT cell receptorTCR sequencing

Identifiers

PMID37949070
PMCPMC10694675
OpenAlexW4388540504

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.